Induction or exacerbation of psoriasis in patients with crohn's disease under treatment with anti-TNF antibodies

Digestion

Volumn 89, Issue 3, 2014, Pages 209-215

  Barthel, Christiane ^a,f   Biedermann, Luc ^a   Frei, Pascal ^a,e   Vavricka, Stephan R ^a,c,d   Kündig, Thomas ^b,d   Fried, Michael ^a,d   Rogler, Gerhard ^a,d   Scharl, Michael ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Division of Gastroenterology and Hepatology Stadtspital Triemli   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e Department for Internal Medicine Seespital Horgen ^*  (Switzerland)

^f ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Adalimumab; Anti TNF agents; Certolizumab pegol; Crohn's disease; Golimumab; Inflammatory bowel disease; Infliximab; Psoriasis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; STEROID;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CROHN DISEASE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PSORIASIS; YOUNG ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FAMILY HISTORY; HUMAN TISSUE; INTESTINE FISTULA; INTESTINE STENOSIS; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN BIOPSY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84900886884     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000358288     Document Type: Review

References (37)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
2. Cho JH, Brant SR: Recent insights into the genetics of inflammatory bowel disease. Gastro-enterology 2011; 140:1704-1712.
3. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448:427-434.
4. Cleynen I, Vermeire S: Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepa-tol 2012; 9:496-503.
5. Gottlieb AB, Evans R, Li S, et al: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534-542.
6. Menter A, Tyring SK, Gordon K, et al: Adali-mumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106-115.
7. Saurat JH, Stingl G, Dubertret L, et al: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558-566.
8. Wollina U, Hansel G, Koch A, et al: Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9:1-14.
9. Cohen JD, Bournerias I, Buffard V, et al: Psoriasis induced by tumor necrosis factor-α antagonist therapy: a case series. J Rheumatol 2007; 34:380-385.
10. Rahier JF, Buche S, Peyrin-Biroulet L, et al: Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroen-terol Hepatol 2010; 8:1048-1055.
11. Shmidt E, Wetter DA, Ferguson SB, et al: Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67:e179-185.
12. Cullen G, Kroshinsky D, Cheifetz AS, et al: Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34:1318-1327.
13. Verea MM, Del Pozo J, Yebra-Pimentel MT, et al: Psoriasiform eruption induced by inflix-imab. Ann Pharmacother 2004; 38:54-57.
14. Harrison MJ, Dixon WG, Watson KD, et al: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor-α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209-215.
15. Collamer AN, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40:233-240.
16. Cullen G, Kroshinsky D, Cheifetz AS, et al: Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34:1318-1327.
17. Fiorino G, Allez M, Malesci A, et al: Review article: anti TNF-α induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29:921-927.
18. Denadai R, Teixeira FV, Steinwurz F, et al: Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2013; 7: 517-524.
19. Guerra I, Algaba A, Pérez-Calle JL, et al: Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012; 6: 518-523.
20. Conklin LS, Cohen B, Wilson L, et al: Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat Rev Gastroenterol Hepatol 2010; 7:174-177.
21. Baumgart DC, Grittner U, Steingräber A, et al: Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011; 17:2512-2520.
22. Ott C, Scholmerich J: Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10:585-595.
23. Patil S, Cross R: Update in the management of extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2013; 15:1-5.
24. Levine JS, Burakoff R: Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (NY) 2011; 7:235-241.
25. Huang BL, Chandra S, Shih DQ: Skin manifestations of inflammatory bowel disease. Front Physiol 2012; 3:13.
26. Strong SA, Koltun WA, Hyman NH, et al: Practice parameters for the surgical management of Crohn's disease. Dis Colon Rectum 2007; 50:1735-1746.
27. Safar B, Sands D: Perianal Crohn's disease. Clin Colon Rectal Surg 2007; 20:282-293.
28. Shaffer VO, Wexner SD: Surgical management of Crohn's disease. Langenbecks Arch Surg 2013; 398:13-27.
29. Maynard CL, Weaver CT: Intestinal effector T cells in health and disease. Immunity 2009; 31:389-400.
30. Strober W, Fuss IJ: Proinflammatory cyto-kines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.e1751.
31. Strober W, Fuss IJ: Proinflammatory cyto-kines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
32. Cuchacovich R, Espinoza CG, Virk Z, et al: Biologic therapy (TNF-α antagonists)-in-duced psoriasis: a cytokine imbalance between TNF-α and IFN-α? J Clin Rheumatol 2008; 14:353-356.
33. Palucka AK, Blanck JP, Bennett L, et al: Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102: 3372-3377.
34. De Gannes GC, Ghoreishi M, Pope J, et al: Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumato-logic conditions. Arch Dermatol 2007; 143: 223-231.
35. Seneschal J, Milpied B, Vergier B, et al: Cyto-kine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br J Dermatol 2009; 161:1081-1088.
36. Tsoi LC, Spain SL, Knight J, et al: Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012; 44:1341-1348.
37. Ellinghaus D, Ellinghaus E, Nair RP, et al: Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012; 90:636-647.